Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Allergy Asthma Proc. 2014 May-Jun;35(3):42-50. doi: 10.2500/aap.2014.35.3747.
This study was designed to determine the percentage of asthma-related emergency department (ED) visits made by patients who recently ran out of their inhaled short-acting beta-agonists or inhaled corticosteroids and to characterize this understudied patient population. A secondary analysis was performed of data from four ED-based multicenter studies of acute asthma during 1996-1998 (n = 64 EDs). In each study, consecutive adult patients, aged 18-54 years, with acute asthma underwent a structured interview that assessed running out of inhaled medications. The analytic cohort comprised 1095 adults. Overall, 324 patients (30%; 95% confidence interval [CI], 27-32%) ran out of either of their inhaled beta-agonists or inhaled corticosteroids during the week before their index ED visit; 311 (28%; 95% CI, 26-31%) ran out of inhaled beta-agonists per se. Among a subset of 518 patients on inhaled corticosteroids, 55 patients (11%; 95% CI, 8-14%) ran out of inhaled corticosteroids. In the multivariable model, predictors of running out of an asthma medication were male sex, non-Hispanic black race, Hispanic ethnicity, no insurance, lower household income, and use of EDs as the preferred source of asthma prescriptions (all p < 0.05). Among patients who ran out of medications, 49% (95% CI, 43-55%) ran out of inhaled beta-agonists and 72% (95% CI, 58-84%) ran out of inhaled corticosteroids, before onset of their acute asthma symptoms. In 1095 adult ED patients with acute asthma, we found that 30% ran out of their inhaled asthma medications before the ED visit. Asthma patients who ran out of medications had sociodemographic characteristics that may help with identification of preventable ED visits. Multifaceted strategies needed to ensure optimal use of inhaled medications are warranted.
这项研究旨在确定最近用完吸入式短效β激动剂或吸入式皮质类固醇的哮喘急诊(ED)就诊患者的比例,并对这一研究不足的患者群体进行特征描述。对 1996-1998 年四个基于 ED 的急性哮喘多中心研究的数据进行了二次分析(n=64 个 ED)。在每个研究中,连续入组年龄在 18-54 岁的急性哮喘成年患者,接受了一项评估吸入药物用尽情况的结构化访谈。分析队列包括 1095 名成年人。总体而言,324 名患者(30%;95%置信区间[CI],27-32%)在他们的 ED 就诊前一周内用完了他们的吸入式β激动剂或吸入式皮质类固醇中的任何一种;311 名患者(28%;95%CI,26-31%)本身用完了吸入式β激动剂。在吸入皮质类固醇的 518 名患者亚组中,有 55 名患者(11%;95%CI,8-14%)用完了吸入皮质类固醇。在多变量模型中,用完哮喘药物的预测因素是男性、非西班牙裔黑人种族、西班牙裔族裔、无保险、较低的家庭收入和将 ED 作为哮喘处方的首选来源(均 P<0.05)。在用完药物的患者中,49%(95%CI,43-55%)在急性哮喘症状发作前用完了吸入式β激动剂,72%(95%CI,58-84%)用完了吸入式皮质类固醇。在 1095 名患有急性哮喘的成年 ED 患者中,我们发现 30%的患者在 ED 就诊前用完了他们的吸入式哮喘药物。用完药物的哮喘患者具有可能有助于识别可预防的 ED 就诊的社会人口统计学特征。需要制定多方面的策略来确保吸入药物的最佳使用。